Cargando…

Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab

The first-in-patient study for olokizumab (OKZ) employed model-based, optimal design and adaptive execution to define the concentration–C-reactive protein (CRP) suppression response. Modeling and exploratory statistics activities involved: reverse engineering of first-in-class (tocilizumab) pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kretsos, K, Jullion, A, Zamacona, M, Harari, O, Shaw, S, Boulanger, B, Oliver, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076804/ https://www.ncbi.nlm.nih.gov/pubmed/24941311 http://dx.doi.org/10.1038/psp.2014.17

Ejemplares similares

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
por: Genovese, Mark C, et al.
Publicado: (2014)

Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling
por: Shaw, Stevan, et al.
Publicado: (2014)

Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment
por: Bure, Irina V., et al.
Publicado: (2020)

Genetic and Clinical Factors Associated with Olokizumab Treatment in Russian Patients with Rheumatoid Arthritis
por: Mikhaylenko, Dmitry S., et al.
Publicado: (2022)

The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis
por: Abuelazm, Mohamed, et al.
Publicado: (2023)

Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies
por: Genovese, Mark C., et al.
Publicado: (2021)

Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study
por: Nasonov, Evgeniy, et al.
Publicado: (2022)

Manufacturing execution systems: optimal design, planning, and deployment
por: Meyer, Heiko, et al.
Publicado: (2009)

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
por: Feist, Eugen, et al.
Publicado: (2022)

First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis
por: Glatt, Sophie, et al.
Publicado: (2017)

IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis
por: Wang, Jianmei, et al.
Publicado: (2013)

Mr. Jullion, on Hydrocephalus Internus
por: Jullion, John
Publicado: (1803)

Creating a Culture of Innovation: Design an Optimal Environment to Create and Execute New Ideas
por: Deschamps-Sonsino, Alexandra
Publicado: (2020)

Optimization of protocol design: a path to efficient, lower cost clinical trial execution
por: Malikova, Marina A
Publicado: (2016)

P03-016 - ANTI IL1 refractory CINCA respondes to ANTI IL6
por: Dueckers, G, et al.
Publicado: (2013)

Leveraging systems biology approaches in clinical pharmacology
por: Melas, Ioannis N, et al.
Publicado: (2013)

Execution time optimization of the level-1 algorithm
por: Witek, M
Publicado: (2003)

Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies
por: Tawara, Ken, et al.
Publicado: (2011)

Economía urbana y cambio sociopolítico en Veracruz : (un estudio de caso de los nueve municipios mas importantes del estado)
por: Zamacona Martínez, Erika
Publicado: (1999)

Economía urbana y cambio sociopolítico en Veracruz (un estudio de caso de los nueve municipios más importantes del estado)
por: Zamacona Martínez, Erika
Publicado: (1999)

Economia urbana y cambio sociopolitico en veracruz
por: Zamacona Martínez, Erika
Publicado: (1997)

Du bon usage des « anti-IL-6 »
por: Dalmat, Yann-Mickael
Publicado: (2022)

Gene expression in active systemic JIA after anti-IL1 and anti-IL6R treatment
por: Ogilvie, EM, et al.
Publicado: (2008)

Executive attention impairment in first-episode schizophrenia
por: Orellana, Gricel, et al.
Publicado: (2012)

Design and execution of clinical trials in orthopaedic surgery
por: Mundi, R., et al.
Publicado: (2014)

Design of cyclodextrin-based systems for intervention execution
por: Lai, Wing-Fu
Publicado: (2019)

Semblanzas de Valle Nacional a Catemaco
por: Ferat de Zamacona, Aurora
Publicado: (1975)

Historia de la cultura en Cosamaloapan de Carpio 1845-1967.
por: Ferat de Zamacona, Aurora
Publicado: (1982)

Apathy is associated with executive functioning in first episode psychosis
por: Faerden, Ann, et al.
Publicado: (2009)

Are chief executive officers more likely to be first-borns?
por: Custódio, Cláudia, et al.
Publicado: (2020)

Design, execution, and interpretation of plant RNA-seq analyses
por: Upton, Racheal N., et al.
Publicado: (2023)

Importancia del contador público como jefe de departamento administrativo en un tribunal de la H. Suprema Corte de Justicia de la Nación
por: Zamacona Sánchez, Esther Aurelia de
Publicado: (1995)

Inpatient stroke rehabilitation: prediction of clinical outcomes using a machine-learning approach
por: Harari, Yaar, et al.
Publicado: (2020)

Optimizing and Assessing Information Technology: Improving Business Project Execution
por: Proctor, K
Publicado: (2011)

Is There an Optimal Autonomic State for Enhanced Flow and Executive Task Performance?
por: Chin, Michael S., et al.
Publicado: (2019)

A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity
por: Rosa, Mickael, et al.
Publicado: (2019)

Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys
por: Desallais, Lucille, et al.
Publicado: (2016)

Remission of autoimmune diabetes by anti-TCR combination therapies with anti-IL-17A or/and anti-IL-6 in the IDDM rat model of type 1 diabetes
por: Jörns, Anne, et al.
Publicado: (2020)

Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma
por: Mochizuki, Daiki, et al.
Publicado: (2015)

Anti-IL6 Autoantibodies in an Infant With CRP-Less Septic Shock
por: Bloomfield, Marketa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tobpd041au6dn7e8u24r2a10pn